برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Quzyttir (cetirizine hydrochloride) Injection Date of Approval: October 4, 2019 Company: TerSera Therapeutics LLC Treatment for: Urticaria Quzyttir (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist indicated for the treatment of acute urticaria in adults and children 6 months of age and older. https://t.me/ppdprogram

➡️Aklief (trifarotene) Topical Cream Date of Approval: October 4, 2019 Company: Galderma Treatment for: Acne Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older. https://t.me/ppdprogram

➡️Rybelsus (semaglutide) Tablets Date of Approval: September 20, 2019 Company: Novo Nordisk Treatment for: Diabetes, Type 2 Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Ibsrela (tenapanor) Tablets Date of Approval: September 12, 2019 Company: Ardelyx, Inc Treatment for: Irritable Bowel Syndrome Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). https://t.me/ppdprogram

➡️Xenleta (lefamulin) Tablets and Injection Date of Approval: August 19, 2019 Company: Nabriva Therapeutics plc Treatment for: Pneumonia Xenleta (lefamulin) is a first-in-class, semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP). https://t.me/ppdprogram

➡️Rinvoq (upadacitinib) Extended-Release Tablets Date of Approval: August 16, 2019 Company: AbbVie Inc. Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, Ankylosing Spondylitis Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. https://t.me/ppdprogram

➡️Wakix (pitolisant) Tablets Date of Approval: August 14, 2019 Company: Harmony Biosciences, LLC Treatment for: Narcolepsy Wakix (pitolisant) is a histamine-3 (H₃) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. https://t.me/ppdprogram

➡️(pretomanid) Tablets Date of Approval: August 14, 2019 Company: TB Alliance Treatment for: Tuberculosis, Resistant Pretomanid is a nitroimidazooxazine antimycobacterial indicated for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). https://t.me/ppdprogram

➡️Accrufer (ferric maltol) Capsules - formerly Feraccru Date of Approval: July 25, 2019 Company: Shield Therapeutics plc Treatment for: Iron Deficiency Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults. https://t.me/ppdprogram

➡️Baqsimi (glucagon) Nasal Powder Date of Approval: July 24, 2019 Company: Eli Lilly and Company Treatment for: Hypoglycemia Baqsimi (glucagon) is a nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycemia in diabetes patients ages 4 years and older. https://t.me/ppdprogram

➡️Recarbrio (imipenem, cilastatin, and relebactam) for Injection Date of Approval: July 16, 2019 Company: Merck Treatment for: Urinary Tract Infection, Intraabdominal Infection, Nosocomial Pneumonia Recarbrio (imipenem, cilastatin, and relebactam) is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adults. https://t.me/ppdprogram

➡️AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: July 15, 2019 Treatment for: Asthma AirDuo Digihaler (fluticasone propionate and salmeterol) is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) combination therapy for the treatment of asthma in patients aged 12 years and older. https://t.me/ppdprogram

➡️Katerzia (amlodipine benzoate) Oral Suspension Date of Approval: July 8, 2019 Company: Silvergate Pharmaceuticals, Inc. Treatment for: High Blood Pressure, Coronary Artery Disease Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults. https://t.me/ppdprogram

➡️Myxredlin (insulin human in sodium chloride) Injection Date of Approval: June 20, 2019 Company: Baxter International Inc. Treatment for: Diabetes, Type 1, Diabetes, Type 2 Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. https://t.me/ppdprogram

➡️Nayzilam (midazolam) Nasal Spray Date of Approval: May 17, 2019 Company: UCB Treatment for: Seizure Clusters Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters. https://t.me/ppdprogram

➡️Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) Extended-Release Tablets Date of Approval: May 2, 2019 Company: AstraZeneca Treatment for: Diabetes, Type 2 Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Duobrii (halobetasol propionate and tazarotene) Lotion Date of Approval: April 25, 2019 Company: Ortho Dermatologics Treatment for: Plaque Psoriasis Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis. https://t.me/ppdprogram

➡️Evenity (romosozumab-aqqg) Injection Date of Approval: April 9, 2019 Company: Amgen Inc. Treatment for: Osteoporosis Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. https://t.me/ppdprogram

➡️Duaklir Pressair (aclidinium bromide and formoterol fumarate) Inhalation Powder Date of Approval: March 29, 2019 Company: Circassia Pharmaceuticals plc Treatment for: COPD Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD. https://t.me/ppdprogram

➡️Sunosi (solriamfetol) Tablets Date of Approval: March 20, 2019 Company: Jazz Pharmaceuticals plc Treatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). https://t.me/ppdprogram